PHARMACOKINETICS (PK) OF VON WILLEBRAND FACTOR (VWF) IN PATIENTS WITH VON WILLEBRAND DISEASE (VWD) AFTER TREATMENT WITH RECOMBINANT VWF OR PLASMA-DERIVED VWF CONCENTRATE.

被引：0
|
作者：
Wang, Y. [1 ]
Marier, J. [2 ]
Vasilinin, G. [2 ]
Berthoz, F. Truong [3 ]
Azen, G. [4 ]
机构：
[1] Shire Human Genet Therapies, Cambridge, MA USA
[2] Certara, Princeton, NJ USA
[3] Baxalta GmbH, Zurich, Switzerland
[4] Baxalta US, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-028
引用
收藏
页码：S36 / S37
页数：2
相关论文
共 50 条
  • [1] TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN ELDERLY PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
    Goudemand, J.
    Derlon, A. Borel
    Henriet, C.
    Susen, S.
    Repesse, Y.
    HAEMOPHILIA, 2022, 28 : 109 - 110
  • [2] TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN PAEDIATRIC PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
    Goudemand, J.
    Borel-Derlon, A.
    Henriet, C.
    Repesse, Y.
    Susen, S.
    HAEMOPHILIA, 2023, 29 : 147 - 147
  • [3] Platelet von Willebrand factor (VWF) MRNA analysis in patients with von Willebrand disease (VWD) and null mutations in VWF gene
    Giacomelli, S.
    Rodeghiero, F.
    Castaman, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 839 - 839
  • [4] Clearance of von willebrand factor (VWF) in type 2 von willebrand disease (VWD): the implications of VWF propeptide (VWFPP) and VWF:Ag levels
    Haberichter, S. L.
    Castaman, G.
    James, P. D.
    Christopherson, P. A.
    Roheghiero, F.
    Lillicrap, D.
    Montgomery, R. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 10 - 10
  • [5] Course of von Willebrand factor (VWF) during pregnancy in women with von Willebrand disease (VWD)
    von Depka, M.
    Detering, C.
    Henkel-Klene, A.
    Doepke, S.
    von Depka, E.
    Ekhlasi-Hundrieser, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 500 - 500
  • [6] Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
    Auerswald, Guenter
    Khayat, Claudia Djambas
    Stasyshyn, Oleksandra
    Iosava, Genadi
    Romashevskaya, Irina
    Lopez, Marta Julia
    Seifert, Wilfried
    Rogosch, Tobias
    JOURNAL OF BLOOD MEDICINE, 2020, 11 : 213 - 225
  • [7] Von willebrand factor (VWF) assays and the diagnosis of von willebrand disease (VWD). Who follows the guidelines?
    Jennings, I
    Kitchen, D.
    Woods, T.
    Munroe-Peart, S.
    Brown, L.
    Kitchen, S.
    Walker, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 152 - 153
  • [8] Comparison between von Willebrand factor (vWF) and vWF antigen II in normal individuals and patients with von Willebrand disease
    de Romeuf, C
    Mazurier, C
    THROMBOSIS AND HAEMOSTASIS, 1998, 80 (01) : 37 - 41
  • [9] Von Willebrand factor (VWF) assays and the diagnosis of von Willebrand disease (VWD). Who follows the guidelines?
    Jennings, I.
    Kitchen, D. P.
    Woods, T. A. L.
    Munroe-Peart, S.
    Brown, L.
    Kitchen, S.
    Walker, I. D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 54 - 54
  • [10] Comparison between plasma von Willebrand factor (VWF) and VWF antigen II level in normal individuals and patients with von Willebrand disease
    DeRomeuf, C
    Mazurier, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 640 - 640
12345